Antares Pharma Reports First Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Antares Pharma (ATRS) Reports In-Line Q1 EPS
May 11, 2015 8:40 AM EDTAntares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $9.22 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More